drugset / Trial / NCT04823624
MBG453 in Lower Risk MDS
NaSingle-groupOpen-labelTreatment
Summary
This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS). The name of the study drug involved in this study is MBG453.
Timeline
- Start
- 2022-01-27
- Primary completion
- 2024-11-12
- Completion
- 2025-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sabatolimab | Monoclonal antibody | — | Intravenous |